



March 18, 2026

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai-400001

**Code: 532321**

**National Stock Exchange of India Limited**

Exchange Plaza,  
C/1, Block G,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai-400051

**Code: Zyduslife**

**Re.:** Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated March 18, 2026, titled **“Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India”**.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Yours faithfully,  
For, **Zydus Lifesciences Limited**

**Dhaval N. Soni**  
**Company Secretary and Compliance Officer**  
**Membership No. FCS7063**

**Encl.:** As above

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



## **Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India**

- *Zydus has developed an innovative formulation of Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen device*
- *Zydus will market the product under the brand names – SEMAGLYN™, MASHEMA™ and ALTERME™*
- *Torrent will market the product under the brand name SEMBOLIC™*
- *Partnership aims to expand access for patients with insufficiently controlled type 2 diabetes mellitus and for chronic weight management*

*Ahmedabad, 18 March, 2026*

Zydus Lifesciences Limited (“Zydus”), an innovation-led global life-sciences company and Torrent Pharmaceuticals Limited (“Torrent Pharma”), a specialty-focused global pharmaceutical company, have entered into a Licensing and Supply Agreement to co-market Semaglutide Injection in the Indian market.

Under the terms of the agreement, Zydus will manufacture and supply the product, while Torrent Pharma has received semi-exclusive rights to co-market the product in India under its own brand name SEMBOLIC™, leveraging its strong presence in chronic therapies and extensive field force across the country.

Zydus will market the product under its brand SEMAGLYN™, MASHEMA™ and ALTERME™, while Torrent Pharma will market the product under its brand SEMBOLIC™. As part of the agreement, Torrent Pharma will pay an upfront licensing fee to Zydus.

Zydus has developed an innovative formulation of Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a reusable patient-friendly pen device, enabling delivery of all strengths for both indications through a single device platform. The formulation combined with the reusable pen device is designed to enhance patient convenience, improve treatment adherence, and support better long-term compliance, addressing key challenges in chronic disease management.



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

- as monotherapy, when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes

It is also indicated for use in adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, and as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of  $\geq 30$  kg/m<sup>2</sup> (obesity) or  $\geq 27$  kg/m<sup>2</sup> (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidaemia.

This partnership brings together Zydus's strong product development and manufacturing capabilities and Torrent Pharma's deep market expertise across India, with the shared objective of improving patient access to advanced GLP-1 therapies for metabolic disorders.

#### **About Zydus Lifesciences Limited**

Zydus Lifesciences Limited is an innovation-led global life sciences company with leadership positions across pharmaceuticals and consumer wellness, supported by an emerging MedTech franchise and a strong international presence across the United States, India, and other global markets. The Group employs more than 29,000 people worldwide, including 1,500 scientists engaged in research and development. The company is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives.

For more details, please visit: [www.zyduslife.com](http://www.zyduslife.com)

#### **About Torrent Pharmaceuticals Limited**

Torrent Pharma, with annual revenues of more than Rs 11,500 crores, is the flagship Company of the Torrent Group, with group revenues of ~Rs 45,000 crores. It is amongst the Top 5 in the therapeutic segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS) and Cosmo-Dermatology. It is a specialty-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. Torrent Pharma has a presence in more than 50 countries and is ranked No. 1 amongst Indian pharmaceutical companies in Brazil and Germany. The company operates 8 manufacturing facilities, of which 5 are USFDA approved, and has invested significantly in R&D infrastructure, employing over 750 scientists.



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

#### **Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878